Personalized Cancer Treatment Systems with AI-Powered SN-38 Formulations

Publication ID: 24-11857630_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Personalized Cancer Treatment Systems with AI-Powered SN-38 Formulations,” Published Technical Disclosure No. 24-11857630_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857630_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,630.

Summary of the Inventive Concept

This inventive concept integrates poly(amino acid) block copolymer formulations of SN-38 with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to create personalized cancer treatment systems with enhanced efficacy and real-time monitoring capabilities.

Background and Problem Solved

The original patent disclosed formulations of SN-38 with poly(amino acid) block copolymers, but these formulations had limitations in terms of personalized dosing, real-time monitoring, and bioavailability. The new inventive concept addresses these limitations by incorporating synergistic combinations of distinct technologies to create a more powerful system.

Detailed Description of the Inventive Concept

The inventive concept comprises a poly(amino acid) block copolymer formulation of SN-38 integrated with machine learning algorithms for predicting optimal dosage regimens, IoT-enabled sensors for monitoring patient response, blockchain-based data management systems for secure and transparent data storage, and nanomaterials like graphene oxide nanoparticles for enhanced bioavailability. Additionally, AI-powered imaging analysis enables real-time tracking of SN-38 distribution and efficacy in the patient's body. The inventive concept also encompasses methods for optimizing SN-38 formulation composition using generative adversarial networks (GANs) and poly(amino acid) block copolymer libraries.

Novelty and Inventive Step

The new inventive concept introduces a synergistic combination of AI, IoT, blockchain, and nanomaterials with poly(amino acid) block copolymer formulations of SN-38, which is not obvious from the original patent. The integration of these distinct technologies provides a novel and non-obvious solution for personalized cancer treatment.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of other machine learning algorithms, different types of IoT sensors, or various nanomaterials. Additionally, the inventive concept could be adapted for other types of cancer treatment or diseases.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of personalized medicine and precision oncology. The target industries include pharmaceutical companies, healthcare providers, and medical research institutions.

CPC Classifications

Section	Class	Group
A	A61	A61K47/34
A	A61	A61K9/08
A	A61	A61K9/19
A	A61	A61K31/4375
A	A61	A61K31/513
A	A61	A61K31/519
A	A61	A61K45/06
A	A61	A61K47/26

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical formulations, drug delivery systems, and cancer treatment technologies, with expertise in polymer chemistry, nanotechnology, and computational drug design methods

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in pharmaceutical sciences or chemical engineering, possessing knowledge of polymer synthesis, drug delivery mechanisms, computational modeling, and interdisciplinary medical technology integration

Obviousness Rationale

A PHOSITA would recognize that integrating computational technologies with existing SN-38 polymer formulations represents a predictable extension of known drug delivery research. The combination of machine learning, IoT sensors, and nanomaterial enhancement with established poly(amino acid) block copolymer technologies follows standard innovation pathways in personalized medicine. The technical elements disclosed in the PTD represent incremental improvements that would be obvious to a skilled practitioner familiar with emerging medical technology trends.

Obvious Combinations & Variations

Source Patent Element

SN-38 composition with poly(amino acid) block copolymer

PTD Variation

Adding graphene oxide nanoparticles for enhanced bioavailability

Obviousness Reasoning

Nanomaterial enhancement of drug delivery is a known technique, and a PHOSITA would recognize graphene oxide as a predictable nanomaterial for improving pharmaceutical absorption

Source Patent Element

Specific weight percentages of SN-38 and copolymer

PTD Variation

Using machine learning algorithms to optimize formulation composition

Obviousness Reasoning

Computational optimization of pharmaceutical formulations is a standard approach, and applying machine learning to existing compositional parameters represents a predictable technological progression

Source Patent Element

Cancer treatment drug formulation

PTD Variation

Integrating IoT sensors and blockchain for patient monitoring

Obviousness Reasoning

Digital health monitoring technologies are increasingly common, and a PHOSITA would find the integration of tracking systems with drug delivery a logical and obvious technological extension

Source Patent Element

Poly(amino acid) block copolymer drug delivery system

PTD Variation

AI-powered imaging analysis for tracking drug distribution

Obviousness Reasoning

Advanced imaging and computational tracking methods are well-established in medical research, representing a predictable application of existing technological capabilities

Source Patent Element

SN-38 cancer treatment formulation

PTD Variation

Generative adversarial networks for formulation optimization

Obviousness Reasoning

Computational design methods are standard in pharmaceutical research, and applying generative AI to drug formulation represents an obvious technological progression

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this Published Technical Disclosure would be considered obvious to a Person Having Ordinary Skill In The Art based on the teachings of US Patent 11857630, as the technical combinations represent predictable extensions of existing pharmaceutical formulation and computational medical technology research, employing standard interdisciplinary innovation techniques known in the field.

Original Patent Information

Patent Number	US 11,857,630
Title	Formulations of SN-38 with poly(amino acid) block polymers
Assignee(s)	TYNDALL FORMULATION SERVICES, LLC